%0 Journal Article
%T 地西他滨在骨髓增生异常综合征治疗中的应用进展<br>Research Progress of Decitabine in Myelodysplastic Syndromes
%A 崔玉姣
%J Advances in Clinical Medicine
%P 73-78
%@ 2161-8720
%D 2024
%I Hans Publishing
%R 10.12677/acm.2024.1451398
%X 骨髓增生异常综合征(myelodysplastic syndrome, MDS)是起源于造血干细胞的一组异质性髓系克隆性疾病，随着表观遗传学的深入研究，发现DNA异常甲基化在MDS的整个疾病过程中起着重要作用。地西他滨(decitabine, DAC)作为去甲基化药物的代表性药物，目前已经广泛应用于MDS的治疗中，本文就DAC在MDS治疗中的应用进展做一综述。<br />
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid clonal diseases originating from hematopoietic stem cells. With the in-depth study of epigenetics, it has been found that abnormal DNA methylation plays an important role in the whole disease process of MDS. Decitabine (DAC), as a representative hypomethylating agent, has been widely used in the treatment of MDS. This article reviews the application progress of DAC in the treatment of MDS.
%K 地西他滨，骨髓增生异常综合征，去甲基化，应用进展<br>Decitabine
%K Myelodysplastic Syndrome
%K Demethylation
%K Application Progress
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=86184